Boehringer Ingelheim Buoyed as Two Medicines Receive Scottish Medicines Consortium (SMC) Green Light for Use within the NHS

BRACKNELL, England--()--Boehringer Ingelheim announced today that following separate full reviews the Scottish Medicines Consortium (SMC) has approved two of its medicines for use by NHS Scotland.1,2

“This is a good day for patients. Living with the consequences of DVT/PE and diabetes can be devastating for people and we are proud to see our medicines able to help those suffering with these illnesses.”

The decision is set to benefit patients’ right across the country and will provide doctors new options for treating two very different conditions.

The two medicines approved for use on NHS Scotland are:

  • Dabigatran Etexilate (Pradaxa®) for the treatment deep vein thrombosis (DVT) and pulmonary embolism (PE) and prevention of recurrent DVT and PE in adults.1
  • Empagliflozin (Jardiance®) for restricted use in treating type 2 diabetes to improve glycaemic control (blood glucose levels) in adults as add on combination therapy. 2

Empagliflozin is approved as an add-on combination therapy, for use with other glucose–lowering medicines including insulin when these, together with diet and exercise, do not provide adequate blood sugar levels.2

Dabigatran’s approval builds on its previous approvals in Scotland for primary prevention of venous thromboembolism (VTE) following elective total hip or knee replacement surgery and the prevention of stroke and systemic embolism in non-valvular atrial fibrillation.1

Full details on the decisions can be found here:

Welcoming the news Zinta Krumins managing director of Boehringer Ingelheim UK and Ireland said

“As a company we are committed to developing innovative new medicines. So the fact the SMC has decided two of our medicines are clinically effective and represent value for money for use within the NHS in Scotland on the same day is testament to this.”

“This is a good day for patients. Living with the consequences of DVT/PE and diabetes can be devastating for people and we are proud to see our medicines able to help those suffering with these illnesses.”

-ENDS-

About Boehringer Ingelheim

The Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 142 affiliates and more than 47,400 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel medications of high therapeutic value for human and veterinary medicine.

Social responsibility is a central element of Boehringer Ingelheim's culture. Involvement in social projects, caring for employees and their families, and providing equal opportunities for all employees form the foundation of the global operations. Mutual cooperation and respect, as well as environmental protection and sustainability are intrinsic factors in all of Boehringer Ingelheim’s endeavors.

In 2013, Boehringer Ingelheim achieved net sales of about 14.1 billion euro, of which 19.5% of the net sales from our Prescription Medicine business is invested into research and development.

For more information please visit www.boehringer-ingelheim.co.uk.

REFERENCES

1. Scottish Medicines Consortium dabigatran etexilate, 110mg, 150mg capsules, SMC No. (995/140 www.scottishmedicines.org.uk last accessed 13th October 2014

2. Scottish Medicines Consortium, empagliflozin, 10m and 25mg tablets, SMC No. 993/14. www.scottishmedicines.org.uk. Last accessed 13th October 2014

~Ends~

Contacts

Boehringer Ingelheim Limited
Esta Keywood
Communications Manager
Tel: +44 (0)1344 742534
esta.keywood@boehringer-ingelheim.com

Release Summary

German pharmaceutical company Boehringer Ingelheim buoyed as two of their medicines receive Scottish Medicines Consortium (SMC) green light for use within NHS Scotland..